<DOC>
	<DOC>NCT00941863</DOC>
	<brief_summary>The primary objective of the study was to define the safety profile and maximum tolerated dose (MTD) of sorafenib tablets in combination with carboplatin and paclitaxel chemotherapy in patients with advanced, refractory solid tumors. The secondary objectives were evaluation of pharmacokinetics (PK) and tumor response of these patients being treated with sorafenib in combination with paclitaxel and carboplatin.</brief_summary>
	<brief_title>Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically confirmed solid tumors Evaluable disease Eastern Cooperative Oncology Group (ECOG) 0 or 1 Life expectancy minimum 12 weeks Congestive heart failure Serious arrhythmias Coronary artery disease (CAD) or ischemia HIV (human immunodeficiency virus) Hepatitis B or C Serious active infection Metastatic brain or meningeal tumors</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Sorafenib</keyword>
	<keyword>Advanced Solid Tumors</keyword>
	<keyword>Maximum tolerated dose</keyword>
	<keyword>Carboplatin and paclitaxel chemotherapy combination</keyword>
</DOC>